{
    "Trade/Device Name(s)": [
        "LZI Methadone II Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K192433",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023317"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJR"
    ],
    "Summary Letter Date": "October 4, 2019",
    "Summary Letter Received Date": "September 5, 2019",
    "Submission Date": "August 30, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.3620"
    ],
    "Regulation Name(s)": [
        "Methadone test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Methadone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Beckman Coulter AU680 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Spectrophotometric measurement at 340 nm"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay",
        "Competitive binding immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Methadone II Enzyme Immunoassay for qualitative and semi-quantitative detection of methadone in urine using automated clinical chemistry analyzers",
    "Indications for Use Summary": "Intended for the qualitative and semi-quantitative determination of methadone in human urine at a cutoff of 300 ng/mL; for prescription use on automated clinical chemistry analyzers, providing preliminary results that require confirmatory testing by GC/MS or LC/MS",
    "fda_folder": "Toxicology"
}